2016: No.21= - £170m
2015: No.22 - £160m
Andrew and Linda Leaver’s Burton-on-Trent based pharmaceutical company Clinigen has made impressive strides in the last year, with increased profits and revenue and a string of strategic acquisitions.
Sales soared by more than 50 per cent in the year to June 30, 2015, with turnover hitting £184.4 million compared to £126 million the previous year, which was itself an increase on the previous year.
The company, which specialises in providing access to unlicensed drugs, reported significant organic growth and acquisitions to boost its product portfolio. Clinigen is now a leader in the lucrative unlicensed medicine supply sector and the clinical trials supply market.
In April Clinigen completed the £225 million acquisition of Surrey’s Idrid Group, as well as a £100 million deal to acquire a global business concentrating on Asia, Africa and Australasia where demand is strong. Last February Clinigen secured a contract win with industry giant AstraZeneca, and the company has extended its exclusive clinical trial distribution agreement with Accord Healthcare for another two years.
When Clinigen was floated on the AIM market in September 2012 it was hailed as one of the best stock market launches of the year. Since then sales and profits have soared.
The £135 million flotation meant a windfall for Andrew and Linda Leaver who sold shares worth £37 million. They retained a stake in the group which Andrew Leaver, 52, formed in 2010, bringing together Keats Healthcare, Clinigen GAP and Clinigen SP. This is now worth at least £115 million.
Clinigen ships drugs to more than 75 countries. In 2014 it increased its product lines following the acquisition of two oncology support products: Savene and Ethyol from AstraZeneca.
The company was set up to supply medicines for clinical trials. It quickly developed into a global provider of specialist pharmaceutical products and services and in 2011 was hailed as the fastest growing private company in the UK in the Sunday Times Fast Track 100. The company is trialling a drug designed to counteract the effects of MRSA-related infections. The drug has the potential to make a huge difference to critically ill patients.
Now it has outlets in Tokyo and Philadelphia, as well as its headquarters and a distribution centre in Burton. The company has a fast growing customer base of pharmaceutical companies, biotechnology specialists and research organisations.
Keats Healthcare has been rebranded as Clinigen CTS, dedicated to sourcing and supplying commercial medicines for clinical study. Clinigen GAP provides pharmaceutical consultancy and development while Clinigen SP concentrates on specialist pharmaceuticals and hospital-only medicines worldwide, commercialising them in niche markets.